主页 > 医药科学 >
【medical-news】妇女认知功能健康队列研究：小剂
TITLE: Low dose aspirin and cognitive function in the women's health study cognitive cohort
TUTHOR: Jae Hee Kang , Nancy Cook , JoAnn Manson2, Julie E Buring, Francine Grodstein
Objective To determine whether low dose aspirin protects women aged 65 or more against cognitive decline.
Design Cohort study within both arms of the women's health study, a randomised, double blind, placebo controlled trial of low dose aspirin for the primary prevention of cardiovascular disease and cancer, 1992-5.
Setting Women's health study, 1998-2004.
Participants 6377 women aged 65 or more.
Interventions Low dose aspirin (100 mg on alternate days) or placebo for a mean of 9.6 years.
Main outcome measures Women had three cognitive assessments at two year intervals by telephone. The battery to assess cognition included five tests measuring general cognition, verbal memory, and category fluency. The primary prespecified outcome was a global score, averaging performance across all tests. The key secondary outcome was a verbal memory score, averaging performance on four measures of verbal memory.
Results At the initial assessment (mean 5.6 years after randomisation) cognitive performance in the aspirin group was similar to that of the placebo group (mean difference in global score -0.01, 95% confidence interval -0.04 to 0.02). Mean decline in the global score from the first to the final cognitive assessment was also similar in the aspirin compared with placebo groups (mean difference 0.01, -0.02 to 0.04). The risk of substantial decline (in the worst 10th centile of decline) was also comparable between the groups (relative risk 0.92, 0.77 to 1.10). Findings were similar for verbal memory; however, a 20% lower risk was observed for decline in category fluency with aspirin (relative risk 0.80, 0.67 to 0.97).
Conclusion Long term use of low dose aspirin does not provide overall benefits for cognition among generally healthy women aged 65 or more. 本人已认领该文编译，48小时后若未提交译文，请其他战友自由认领 本人已认领该文编译，48小时后若未提交译文，请其他战友自由认领 RESOURCE: BMJ, doi:10.1136/bmj.39166.597836.BE (published 27 April 2007)
资源：BMJ, doi:10.1136/bmj.39166.597836.BE（刊登于2007年4月27日）
TITLE: Low dose aspirin and cognitive function in the women's health study cognitive cohort
标题：在对妇女的健康研究认知列队中：小剂量阿司匹林同认知功能的关系
TUTHOR: Jae Hee Kang , Nancy Cook , JoAnn Manson2, Julie E Buring, Francine Grodstein
AUTHOR？：Jae Hee Kang , Nancy Cook , JoAnn Manson2, Julie E Buring, Francine Grodstein
Objective To determine whether low dose aspirin protects women aged 65 or more against cognitive decline.
目的：为了确定低剂量阿司匹林对65岁或年龄更大的妇女认知功能的衰退是否有抵抗作用
Design Cohort study within both arms of the women's health study, a randomised, double blind, placebo controlled trial of low dose aspirin for the primary prevention of cardiovascular disease and cancer, 1992-5.
设计：在两组妇女健康研究的列队研究中，采用一个随机的，双盲的，安慰对照试验，用低剂量阿司匹林对心脑血管疾病和癌症进行一级预防，1992-5。
Setting Women's health study, 1998-2004.
背景：妇女健康研究，1998-2004。
Participants 6377 women aged 65 or more.
参与者：6377名年龄在65岁或以上的妇女
Interventions Low dose aspirin (100 mg on alternate days) or placebo for a mean of 9.6 years.
介入治疗：低剂量阿司匹林（100mg每两天）或安慰剂服用平均9.6年。
Main outcome measures Women had three cognitive assessments at two year intervals by telephone. The battery to assess cognition included five tests measuring general cognition, verbal memory, and category fluency. The primary prespecified outcome was a global score, averaging performance across all tests. The key secondary outcome was a verbal memory score, averaging performance on four measures of verbal memory.
主要结果的测量方法：妇女每隔两年通过电话有三项认知评估。这组认知评估包括五项考试测试的一般认知，非文字记忆和分类流畅性。事先规定的主要判断指标是一个整体评分：平均表现通过所有测试。次要判断指标的关键点是一项非文字记忆分数：非文字记忆的四项测试的平均表现。
Results At the initial assessment (mean 5.6 years after randomisation) cognitive performance in the aspirin group was similar to that of the placebo group (mean difference in global score -0.01, 95% confidence interval -0.04 to 0.02). Mean decline in the global score from the first to the final cognitive assessment was also similar in the aspirin compared with placebo groups (mean difference 0.01, -0.02 to 0.04). The risk of substantial decline (in the worst 10th centile of decline) was also comparable between the groups (relative risk 0.92, 0.77 to 1.10). Findings were similar for verbal memory; however, a 20% lower risk was observed for decline in category fluency with aspirin (relative risk 0.80, 0.67 to 0.97).
阅读本文的人还阅读：
作者:admin@医学,生命科学 2011-02-16 17:11
医学,生命科学网